Skip to main content

ShanX Medtech

Category: AI in Healthcare

An AI-driven in-vitro diagnostic platform that provides ultra-rapid antibiotic susceptibility testing (AST) results directly from clinical samples in under 60 minutes. ShanX Medtech was founded in 2019. The company is led by Sophia E. Shanko. Based in Eindhoven, Netherlands. Team size: 11-50. Total funding raised: €24.0M. Latest round: Seed round (€15.0M, Jan 2025). Key investors include Borski Fund, Invest-NL, Brabantse Ontwikkelings Maatschappij (BOM), NextGen Ventures, CbusineZ.

Founded
2019
Headquarters
Eindhoven, Netherlands
Team size
11-50
Total funding
€24.0M

Value proposition

Enables a 'test-before-treat' approach by reducing the diagnostic window from days to under one hour, ensuring patients receive the correct antibiotic immediately while combating antimicrobial resistance (AMR).

Products and solutions

KAIROS: The core point-of-care diagnostic platform/device., FLORA™: Proprietary chemical composition used to monitor pathogen metabolism in real-time., UTI Diagnostic Kit: Advanced clinical stage test for Urinary Tract Infections., Wound Infection & Blood Culture Tests: Early-stage clinical and pre-clinical pipeline applications.

Unique value

Unlike traditional methods that rely on bacterial growth (taking 24-48 hours), ShanX monitors the metabolic response of individual microbes to antibiotics in real-time, delivering results in less than an hour.

Target customer

Clinical microbiologists, ICU physicians, emergency departments, hospital diagnostic labs, and military medical units.

Industries served

In-Vitro Diagnostics (IVD), Clinical Microbiology, Healthcare AI, Military Medicine, Infectious Disease Management

Technology advantage

Combines high-precision microfluidics with proprietary metabolic signaling chemistry (FLORA™) and AI algorithms to eliminate the need for time-consuming pre-culture steps.

How they differentiate

ShanX eliminates the traditional 24-48 hour 'pre-culture' growth period. While competitors like Accelerate Diagnostics require a positive blood culture (taking hours/days), ShanX uses AI-driven metabolic monitoring (FLORA™) to deliver results directly from clinical samples in under 60 minutes.

Main competitors

Accelerate Diagnostics, Gradientech, Pattern Bioscience, Specific Diagnostics (bioMérieux)

Key partnerships

Erasmus Medical Center (Clinical validation partner), AMR Global (Feasibility and clinical strategy), European Commission/HERA (HADEA contract for pandemic preparedness), Eindhoven University of Technology (Academic and IP partner), Dutch Ministry of Defense (Military medicine applications)

Notable customers

Erasmus Medical Center (Clinical Partner), Dutch Ministry of Defense, European Commission (HERA/HADEA)

Major milestones

Founded as a spin-off from Eindhoven University of Technology in 2019, Awarded €8.85M contract by the European Commission (HERA) in 2023, Closed oversubscribed €15M Seed funding round in January 2025, Validation of KAIROS platform for UTI and Blood Culture applications

Growth metrics

Transitioned from a TU Eindhoven spin-off to a clinical-stage medtech company; secured one of the largest European HERA contracts for pandemic preparedness.

Market positioning

Deep-tech disruptor in the Antimicrobial Resistance (AMR) space, positioned as the fastest 'test-before-treat' diagnostic platform for critical care settings.

Geographic focus

Europe (Headquartered in Netherlands), with expansion plans for North America and global clinical microbiology markets.

Patents and IP

Spin-off from Eindhoven University of Technology (TU/e) with proprietary IP; CTO Henk Stapert is a co-inventor of over 25 granted patent applications in the medtech space.

About Sophia E. Shanko

PhD in Mechanical Engineering (Microfluidics) from Eindhoven University of Technology (TU/e); previous experience as an intern at GE Healthcare and researcher at TU/e focusing on high-precision diagnostics.

Official website: